Spotlight: Implications of Just Published New PTAB Rules
The use of inter partes review (IPR) to challenge bio/pharma patents has grown significantly — with the number nearly doubling in 2015 alone. While relatively few of them have reached final decisions, what gives some challengers the winning edge?
Please join our experienced attorneys for a discussion on the key challenges you could face with your next IPR, as well as your overall strategies for patent litigation and enforcement, and how to prepare to address them.
Topics include:
- Determining trends based on the first 105+ bio/pharma IPR petitions to be filed
- Discovering the most vulnerable types of bio/pharma patents
- Learning how to prosecute bio/pharma patents to withstand IPR
- Employing tactics to help prevent an institution decision
- Understanding more about biosimilar and biologics-related IPRs
- Reviewing updates on PTAB rule changes
Speakers
Stephen Maebius, Partner, IP Department, Foley & Lardner LLP
Kristel Schorr, Partner and Chair, Chemical, Biotechnology & Pharmaceutical Practice, Foley & Lardner LLP
Moderator
Etsuo Doi, Managing Partner, Tokyo Office, Foley & Lardner LLP
People
Related Insights
30 August 2024
Viewpoints
FTC’s Ban on Noncompete Agreements Is Blocked
04 September 2024
Events
Navigating Intellectual Property While Building with AI
Foley Partner Eric Sophir will present on the topic of “Navigating Intellectual Property while building with AI” at the Martin Luther King Jr. Memorial Library on Wednesday, September 4, 2024, from 4:00 p.m.-5:00 p.m. EDT.
29 August 2024
Manufacturing Industry Advisor
2024 CPSC and FDA Enforcement Trends
The enforcement trends of 2023 have continued into 2024, especially with respect to the U.S. Consumer Product Safety Commission and the U.S. Food and Drug Administration.